Where does Nektar Therapeutics rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nektar Therapeutics ranks #2,030 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nektar Therapeutics hold?

Nektar Therapeutics holds 196 US utility patents granted between 2015 and 2025, spanning 27 technology areas.

What is Nektar Therapeutics's Innovation Score?

Nektar Therapeutics has an Innovation Score of 47.1 out of 100 (top 19% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Nektar Therapeutics's patent grant rate increasing or decreasing?

Nektar Therapeutics's recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Nektar Therapeutics's patents?

Nektar Therapeutics's patents average 12.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nektar Therapeutics patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Nektar Therapeutics

Q: What technology areas does Nektar Therapeutics focus on?

Nektar Therapeutics's top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 175 patents. Grants appear in 27 CPC subclasses total.

USPTO PatentsView assignee record - 196 granted patents across 27 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nektar ranks #2,030 of 49,997 tracked US assignees by granted-patent volume, with 196 patents across 27 technology areas.

#2,030
of 49,997 US assignees by volume: Top 19%
by Innovation Score (47.1/100): 12.5
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2030 · US Corporation #2,030 · 196 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MID 196 grants
TOP-DECILE #2,030/49,997
PHOTO-FINISH Biomet Sports Medicine
CPC-FOCUS A61K · 27 areas
INNOV-PAR 47.1/100
CLAIMS-RICH 12.5 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Biomet Sports Medicine, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Aten International · near

47
Dreamworks Animation · near

47
Intrabio · near

47
MVE Biological… · near

47
Nektar Therapeutics · this assignee

47
3D Lighting… · lowest

7

What this shows Nektar's Innovation Score is 47.1/100 (top 19% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Nektar's grants concentrate

Nektar Therapeutics is a focused PatentsView assignee: 27 CPC subclasses with 89.3% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2015 (41 grants) versus a trough of 5 in 2024. By volume, Nektar sits between Sorin CRM SAS and China Mobile Communications Group Co., Ltd..

Nektar's three-year grant acceleration

From 2019–2021 to 2022–2024, Nektar Therapeutics moved from 45 to 20 grants (0.44x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,804. See the growth leaderboard.

Sorin CRM SAS

197
Securus

197
Timotion Technolo…

197
Biomet Sports Med…

196
Olympus Winter &…

196
Specialized Bicyc…

196
True Velocity IP…

196
Nektar Therapeuti… ◀

196
China Mobile Comm…

195

What this shows Nektar holds 196 patents at rank #2,030, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nektar

By rank, the assignees closest to #2,030 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Nektar's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Nektar, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (47 here).

Dreamworks Animation LLC 47 Aten International Co., Ltd 47 Intrabio Ltd. 47 MVE Biological Solutions US, LLC 47

Similar claim depth

Nearest assignees by average claims per patent (12.5 here).

Mandom Corporation 12.5 avg Ideal Power Inc. 12.5 avg Auras Technology Co., Ltd. 12.5 avg THE Board OF Trustees OF THE University OF Arkansas 12.5 avg

Nektar's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 19% higher than 81% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Nektar Therapeutics patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	41	20.9%
2016	39	19.9%
2017	27	13.8%
2018	19	9.7%
2019	18	9.2%
2020	15	7.7%
2021	12	6.1%
2022	8	4.1%
2023	7	3.6%
2024	5	2.6%
2025partial year	5	2.6%

Which technologies does Nektar Therapeutics patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 175

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 146

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 63

C07D - Heterocyclic Compounds 59

C07C - Acyclic OR Carbocyclic Compounds 30

C07K - Peptides 28

C08L - Compositions OF Macromolecular Compounds 27

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 13

B05B - Spraying APPARATUS; Atomising APPARATUS; Nozzles 9

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 8

C08K - Use of inorganic or non-macromolecular organic substances as compounding ingredients 6

B01D - Separation 4

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

Y10T - Technical Subjects Covered BY Former US Classification 3

Top 15 of 27 technology areas

Where it ranks

Overall rank by patents

#2,030

of 49,997 tracked assignees

Innovation Score

47.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Nektar Therapeutics's patent record in context - here's where to go next.

Nektar Therapeutics's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 89.3% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #2,030 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nektar Therapeutics against Sorin CRM SAS, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 47.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.